SCHEMBL3928666

SCHEMBL3928666

NC(=O)Nc1ccccc1NC(N)=O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.67
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
RECQL P46063 1/20 0.56
MAPT P10636 1/20 0.56
GFER P55789 1/20 0.56
POLB P06746 1/20 0.54
CYP1A2 P05177 1/20 0.54
MAPK1 P28482 2/20 0.50
PEPD P12955 1/20 0.50
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 2/20 0.48
IKBKB O14920 1/20 0.47
TOP1 P11387 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29840068 1.00 GAA (0.67) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL15259585 0.89 KDM4E (0.57) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL7417077 0.89 GAA (0.57) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL30275531 0.87 ALDH1A1 (0.58) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL250263 0.87 HDAC3 (0.64) GAAKDM4EMAPK1NPC1RAB9A
SCHEMBL29807803 0.87 GAA (0.61) GAAKDM4EALDH1A1MAPTLMNA
SCHEMBL11649214 0.87 GAA (0.61) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL11760578 0.87 GAA (0.61) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL5545365 0.87 GAA (0.55) GAAKDM4EALDH1A1SMN1; SMN2RECQL
SCHEMBL3859948 0.87 GAA (0.61) GAAKDM4EALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459014-B2 Radiation curable inks containing curable gelator additives XEROX CORPORATION (US) 2008-12-02 US claimed
EP-1681323-B1 Radiation curable inks XEROX CORP (US) 2007-10-31 EP claimed
US-20060159850-A1 Radiation curable inks containing curable gelator additives XEROX CORPORATION (US) 2006-07-20 US claimed
EP-1681323-A1 Radiation curable inks Xerox Corporation (US) 2006-07-19 EP claimed
US-11046645-B2 Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition ASAHI KASEI CHEMICALS CORPORATION (JP) 2021-06-29 US disclosed
EP-2641896-B1 SEPARATION METHOD ASAHI CHEMICAL IND (JP) 2020-10-14 EP disclosed
EP-3363785-B1 ISOTHIOCYANATE PRODUCTION METHODS ASAHI CHEMICAL IND (JP) 2020-09-16 EP disclosed
US-20190233371-A1 Isothiocyanate Production Method, Composition for Transporting and Storing N-Substituted O-Substituted Thiocarbamate, and Isothiocyanate Composition ASAHI KASEI KABUSHIKI KAISHA (JP) 2019-08-01 US disclosed
EP-3214071-B1 ISOTHIOCYANATE COMPOSITION ASAHI CHEMICAL IND (JP) 2019-07-03 EP disclosed
US-10308601-B2 Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition ASAHI KASEI CHEMICALS CORPORATION (JP) 2019-06-04 US disclosed
EP-3363785-A1 ISOTHIOCYANATE PRODUCTION METHODS Asahi Kasei Chemicals Corporation (JP) 2018-08-22 EP disclosed
US-9950273-B2 Method of separation ASAHI KASEI CHEMICALS CORPORATION (JP) 2018-04-24 US disclosed
EP-1631261-A2 PRODUCTION OF SMALL PARTICLES Applied NanoSystems B.V. (NL) 2006-03-08 EP disclosed
WO-2004103347-A2 PRODUCTION OF SMALL PARTICLES APPLIED NANOSYSTEMS B.V. (NL) 2004-12-02 WO disclosed
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition L'OREAL (FR) 2003-05-15 US disclosed
EP-1264589-A1 Use of a polar additive in a cosmetic composition containing a structured liquid oil phase by at least one organogelator to give a thixotropic character L'OREAL (FR) 2002-12-11 EP disclosed
EP-0024526-B1 EPOXY BASED SYNTHETIC SOLDER AMERICAN CYANAMID COMPANY (US) 1984-06-13 EP disclosed
US-4273686-A 1,1'-O-PHENYLENEBIS(3,3-DIMETHYLUREA), DICYANDIAMIDE, FILLER, QUICK-SETTING AMERICAN CYANAMID COMPANY (US) 1981-06-16 US disclosed
EP-0024526-A2 Epoxy based synthetic solder AMERICAN CYANAMID COMPANY (US) 1981-03-11 EP disclosed
US-3940365-A PHENOLIC ANTIOXIDANT AND AN UREA OR AN OXALIC ACID DIAMIDE OR AN AZODICARBOXYLIC AMIDE HOECHST AKTIENGESELLSCHAFT (DT) 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046645-B2 Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition TST, SLCO4C1, SLCO2B1 GAA 2074/4885KDM4E 4047/4885ALDH1A1 723/4885
US-20190233371-A1 Isothiocyanate Production Method, Composition for Transporting and Storing N-Substituted O-Substituted Thiocarbamate, and Isothiocyanate Composition TST, SLCO4C1, SLCO2B1 GAA 2074/4885KDM4E 4047/4885ALDH1A1 723/4885
US-20030091520-A1 Use of at least one polar additive in a cosmetic composition comprising a liquid fatty phase structured by at least one molecular organogelator, to impart a thixotropic character to the composition PLIN3, CUTA, FABP4 GAA 4196/4885KDM4E 3681/4885ALDH1A1 2187/4885
US-10308601-B2 Isothiocyanate production method, composition for transporting and storing N-substituted O-substituted thiocarbamate, and isothiocyanate composition TST, SLCO4C1, SLCO2B1 GAA 2074/4885KDM4E 4047/4885ALDH1A1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.